Parameter
| Biomarker | SSTR2A | Full name | Somatostatin receptor subtype 2A | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Treatment prediction, diagnosis |
| Disease | Pancreatic Neuroendocrine Tumors | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Tissue/serum (IHC, PET/CT) | ||
| Pathobiological Mechanisms | Somatostatin receptor subtypes, which mediate growth inhibitory signals, are highly expressed in PANnets | ||||
| Clinical Availability Status | The guidelines recommend: IHC testing to guide peptide receptor radionuclide therapy (PRRT); 68Ga-DOTATATE PET/CT is used for staging, and patients with high uptake have better efficacy of PRRT | ||||
| Notes and Dynamics | The expression level of PRRT was negatively correlated with Ki-67, and the expression rate of G1/G2 was higher than that of G3 | ||||